
Abstracts of the 2025 Annual Meeting of the ALEH
More infoAdiposity is associated with an increased risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD).
Verify the association between liver fibrosis and visceral adiposity in MASLD by Dual-energy X-ray absorptiometry (DXA) method.
Materials and MethodsIn a cross-sectional study, assessment of MASLD and significant fibrosis (F≥2) were performed by ultrassonography and transient elastography, respectively. Dual-energy X-ray absorptiometry (DXA) were performed to assess fat mass index (FMI), visceral adipose tissue (VAT)and android-to-gynoid (A/G) ratio. Data are reported as median (IQR) or n (%); p < 0.05 was considered significant
Results141 participants were enrolled, 32(22.7%) had hepatic fibrosis. Age was 62.0(55.0–68.0) years, and 118(83.7%) were women. Adiposity parameters were waist-to-height ratio (WHtR) 0.66 (0.59–0.71); abdominal circumference (AC) 105.0(94.4–114.1) cm; fat mass index (FMI) 13.94 (10.50–17.20) kg/m2; VAT 1784 (1203–2430) cm3; and A/G 1.13 (1.04–1.23). The prevalence of obesity (BMI ≥ 30 kg/m2), high FMI (> 14 kg/m2), and A/G > 1 was 45(31.9%), 52(36.9%), and 130(92.2%) respectively. The groups with and without fibrosis were compared. Age and sex were similar between groups. Those with fibrosis had significantly higher WHtR, AC, VAT, trunk fat mass, android fat mass, and total fat mass. (Table 1).
ConclusionsThis study shows that central and visceral adiposity are significantly linked to liver fibrosis. These findings are measured by DXA, an accurate method, and are supported by simple and cost-effective clinical measures such as WHtR and AC.
Conflict of interest: None
Table1. Clinical and body composition characteristics
Legend: Values are presented as median (interquartile range). Bold p-values indicate statistical significance (p < 0.05).






